Definition/General

Introduction:
-Primary small cell carcinoma of the breast is an extremely rare and highly aggressive malignancy
-It is a type of poorly differentiated neuroendocrine carcinoma, histologically identical to small cell carcinoma of the lung
-The diagnosis requires the exclusion of a metastasis from the lung or another primary site.
Origin: It is thought to arise from neuroendocrine cells in the breast or from the neuroendocrine differentiation of a ductal carcinoma.
Classification: It is classified as a subtype of poorly differentiated neuroendocrine carcinoma of the breast.
Epidemiology:
-Extremely rare, representing less than 0.1% of all breast cancers
-It typically affects older women.

Clinical Features

Presentation:
-Presents as a large, rapidly growing, palpable breast mass
-Axillary lymph node metastasis is common at presentation.
Symptoms:
-A painless breast lump is the most common symptom
-Paraneoplastic syndromes can occur but are rare.
Risk Factors: No specific risk factors are known.
Screening:
-Usually presents as a palpable mass
-Mammographic and ultrasound findings are non-specific.

Master Breast Small Cell Ca Pathology with RxDx

Access 100+ pathology videos and expert guidance with the RxDx app

Gross Description

Appearance:
-A large, fleshy, tan-white mass with infiltrative borders
-Necrosis and hemorrhage are common.
Characteristics: The tumor is typically large and soft.
Size Location: Can occur anywhere in the breast.
Multifocality: Rare.

Microscopic Description

Histological Features:
-The tumor is composed of sheets of small, round, blue cells with scant cytoplasm, finely granular "salt-and-pepper" chromatin, and inconspicuous nucleoli
-There is a high mitotic rate, extensive necrosis, and nuclear molding.
Cellular Characteristics:
-The cells are small, with a high N/C ratio
-The nuclear chromatin is finely granular
-Nuclear molding is a key feature.
Architectural Patterns:
-The growth pattern is diffuse and infiltrative
-Azzopardi effect (basophilic staining of blood vessel walls due to DNA from necrotic tumor cells) can be seen.
Grading Criteria: This is a high-grade carcinoma by definition.

Immunohistochemistry

Positive Markers:
-The tumor cells are positive for neuroendocrine markers such as synaptophysin, chromogranin A, and CD56
-They are also positive for TTF-1 in about 50% of cases
-They are positive for cytokeratins (CAM5.2, AE1/AE3).
Negative Markers:
-Typically triple-negative (ER, PR, and HER2 negative).
Diagnostic Utility:
-IHC is essential for diagnosis and to differentiate from other small round blue cell tumors
-The main challenge is excluding a lung primary.
Molecular Subtypes: Classified as triple-negative.

Molecular/Genetic

Genetic Mutations:
-The molecular genetics are not well characterized but often involve TP53 and RB1 mutations, similar to small cell lung cancer.
Molecular Markers: No specific molecular markers are routinely used for diagnosis.
Prognostic Significance:
-The prognosis is very poor, with a high rate of early and widespread metastasis
-The behavior is similar to that of small cell lung cancer.
Therapeutic Targets:
-Treatment is primarily with platinum-based chemotherapy, similar to small cell lung cancer
-The role of surgery and radiation is less clear.

Differential Diagnosis

Similar Entities:
-Metastatic small cell carcinoma from the lung
-Lymphoma
-Lobular carcinoma.
Distinguishing Features:
-Excluding a lung primary is crucial and requires clinical and radiological correlation
-Lymphoma is negative for cytokeratins and positive for lymphoid markers (e.g., CD45)
-Lobular carcinoma is ER-positive and negative for neuroendocrine markers.
Diagnostic Challenges:
-The main challenge is confirming a primary breast origin
-The presence of an in situ component (DCIS) with transition to small cell carcinoma is the best evidence but is rarely found.
Rare Variants: The entire entity is a rare variant.

Sample Pathology Report

Template Format

Sample Pathology Report

Complete Report: This is an example of how the final pathology report should be structured for this condition.

Specimen Information

[specimen type], measuring [size] cm in greatest dimension

Diagnosis

[diagnosis name]

Classification

Classification: [classification system] [grade/type]

Histological Features

Shows [architectural pattern] with [nuclear features] and [mitotic activity]

Size and Extent

Size: [X] cm, extent: [local/regional/metastatic]

Margins

Margins are [involved/uninvolved] with closest margin [X] mm

Lymphovascular Invasion

Lymphovascular invasion: [present/absent]

Lymph Node Status

Lymph nodes: [X] positive out of [X] examined

Special Studies

IHC: [marker]: [result]

Molecular: [test]: [result]

[other study]: [result]

Final Diagnosis

Final diagnosis: [complete diagnosis]